ANVS
Annovis Bio, Inc.·Healthcare
1.59
1.852%(−0.03)
Market ClosedLast Updated: — ET
52W L: $1.1952W H: $5.50
ANVS NEWS
globenewswire.com
1d ago
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).
globenewswire.com
2d ago
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.
defenseworld.net
6d ago
Michael Hoffman Acquires 713,800 Shares of Annovis Bio (NYSE:ANVS) Stock
Annovis Bio, Inc. (NYSE: ANVS - Get Free Report) Director Michael Hoffman bought 713,800 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was acquired at an average price of $2.10 per share, for a total transaction of $1,498,980.00. Following the completion of the purchase, the director directly owned 3,288,539 shares
globenewswire.com
Apr 2
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No.
globenewswire.com
Mar 31
Annovis Publishes Historical Review of Buntanetap in The Scientist
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer's Disease Drug”, examining the history of discovery and development of buntanetap, the Company's lead drug candidate.
globenewswire.com
Mar 19
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitoring in Annovis Bio's Parkinson's disease clinical trial.
